Document Detail

The effect of L-thyroxine replacement therapy on lipid based cardiovascular risk in subclinical hypothyroidism.
MedLine Citation:
PMID:  15762035     Owner:  NLM     Status:  MEDLINE    
The aim of our study was to assess the changes in serum lipid profiles after replacement therapy with L-T4 in patients with subclinical hypothyroidism (SCH), and to see whether there is an improvement in dyslipidemia based cardiovascular risk. Thirty non-smoker pre-menopausal women with newly diagnosed SCH (TSH between 4 and 10 microIU/ml) were involved in our study; twenty-six euthyroid healthy subjects were used as control group. TSH, free T3 (FT3), free T4 (FT4), total cholesterol (TC), triglyceride (TG), HDL cholesterol (HDL-C) and LDL cholesterol (LDL-C) levels were measured before and after 6 months of L-T4 (50-100 microg/ day) therapy. TSH levels were targeted as < 2.0 microIU/ml. LDL-C was calculated using the Friedewald formula, while the cardiovascular risk was assessed with the TC/HDL-C ratio. Pre-treatment serum TC and LDL-C concentrations in SCH patients were significantly higher than those of euthyroid subjects (199.8 +/- 22.2 vs 181.5 +/- 24.6 mg/dl, p < 0.01; 146.3 +/- 26.1 vs 124.8 +/- 12 mg/dl, p < 0.001, respectively). TC, LDL-C levels and the TC/HDL-C ratio were reduced significantly after 6-month replacement therapy (-21.1 +/- 34.4 mg/dl or -10.5%, p < 0.01; -21.5 +/- 30.3 mg/dl or -14.7%, p < 0.001, respectively; and TC/HDL-C from 4.8 +/- 0.6 to 4.1 +/- 0.5 mg/dl, p < 0.01), while body mass index (BMI) values did not change. In conclusion, even mild elevations of TSH are associated with changes in lipid profile significant enough to raise the cardiovascular risk ratio, and these changes are corrected once the patients have been rendered euthyroid.
R Serter; B Demirbas; B Korukluoglu; C Culha; E Cakal; Y Aral
Related Documents :
18585505 - Prevalence and extent of dyslipidemia and recommended lipid levels in us adults with an...
6360415 - The influence of changes in lipid values induced by cholestyramine and diet on progress...
8528755 - Cholesterol and coronary heart disease: predicting risks in men by changes in levels an...
16280425 - Individual variability in cardiovascular disease risk factor responses to low-fat and l...
22294725 - The influence of food restriction versus ad libitum feeding of chow and purified diets ...
22407725 - Assessment of the high-dose concept and level of control provided by mon 87701 × mon 89...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Journal of endocrinological investigation     Volume:  27     ISSN:  0391-4097     ISO Abbreviation:  J. Endocrinol. Invest.     Publication Date:  2004 Nov 
Date Detail:
Created Date:  2005-03-14     Completed Date:  2005-06-07     Revised Date:  2005-11-17    
Medline Journal Info:
Nlm Unique ID:  7806594     Medline TA:  J Endocrinol Invest     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  897-903     Citation Subset:  IM    
Endocrinology and Metabolism, Ankara Education and Research Hospital, Ankara, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Body Mass Index
Cardiovascular Diseases / etiology*,  prevention & control*
Cholesterol / blood
Hypothyroidism / complications,  drug therapy*
Lipid Metabolism
Lipids / blood*
Risk Factors
Thyroxine / therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Lipids; 57-88-5/Cholesterol; 7488-70-2/Thyroxine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Informed consent in China: quality of information provided to participants in a research project.
Next Document:  Effects of 17beta-estradiol, tamoxifen and raloxifene on the protein and mRNA expression of interleu...